The Northwestern University-backed neurologic disorder therapy developer floated at the top of its range, increasing the share volume at the same time.
Aptinyx, a US-based neurologic disorder drug developer backed by Northwestern University and spinout-focused investment firm Osage University Partners, raised approximately $102m when it floated on the Nasdaq Global Select Market yesterday.
The company issued 6.4 million shares priced at $16.00 each, at the top of the initial public offering’s $14 to $16 range, giving it a $520m market capitalisation. The number of shares was increased from 5.3 million.
Aptinyx’s shares opened at $17.40 yesterday on its first day of…
